Clinical trial · Interventional
Local Treatment With RP for Newly-diagnosed mPCa
Local Treatment With Radical Prostatectomy (RP) for Newly-diagnosed Metastatic Prostate Cancer (mPCa).
NCT02138721CI-TRIAL-00072434LoMPunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to evaluate the role of local treatment with radical prostatectomy in patients with newly-diagnosed metastatic hormone-sensitive prostate cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm Metastasis | — | UNRESOLVED | — |
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radical Prostatectomy (RP) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- No local treatment
- description
- Routine care in metastatic prostate cancer.
- type
- EXPERIMENTAL
- label
- Local treatment
- description
- Radical Prostatectomy (RP) + routine care in metastatic prostate cancer.
- interventionNames
- Procedure: Radical Prostatectomy (RP)
Primary outcomes (2)
- measure
- Castration Refractory Prostate Cancer Progression-Free Survival
- timeFrame
- up to 10 years
- description
- From date of inclusion until the date of Castration Refractory Prostate Cancer (CRPC) defined according to European Association of Urology (EAU) guidelines, or date of death from any cause, whichever came first, assessed up to 10 years. \[months\]
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of prostate adenocarcinoma, confirmed by histology * Newly diagnosis of metastatic disease (stage TanyNanyM+) * Life expectancy ≥2y based on comorbid conditions, WHO performance status 0-2 * Written informed consent, male ≥18yo * Willing and expected to comply with study protocol and follow-up schedule * Multidisciplinary Oncologic Consultation (MOC) approval Exclusion Criteria: * Previous local or systemic treatment for prostate cancer * Metastatic brain disease, leptomeningeal disease or imminent spinal cord compression * Symptoms clearly related to metastatic lesions * Any other previous or current (malignant) disease which, in the judgment of the responsible physician, is likely to interfere with LoMP treatment or assessment
References
Publications (1)
- RESULTPoelaert F, Verbaeys C, Rappe B, Kimpe B, Billiet I, Plancke H, Decaestecker K, Fonteyne V, Buelens S, Lumen N. Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial. Urology. 2017 Aug;106:146-152. doi: 10.1016/j.urology.2017.02.051. Epub 2017 Apr 20. PMID 28435034